Status:
COMPLETED
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
Lead Sponsor:
Sanofi Pasteur, a Sanofi Company
Conditions:
Influenza
Influenza Immunization
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza...
Detailed Description
Approximately 6 months
Eligibility Criteria
Inclusion
- Having given written informed consent prior to undertaking any study-related procedure.
Exclusion
- Participants are excluded from the study if any of the following criteria apply:
- Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
April 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 17 2023
Estimated Enrollment :
388 Patients enrolled
Trial Details
Trial ID
NCT06118151
Start Date
April 11 2022
End Date
February 17 2023
Last Update
November 7 2023
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Peninsula Research Associates Site Number : 8400013
Rolling Hills Estates, California, United States, 90274
2
Optimal Research Site Number : 8400026
San Diego, California, United States, 92108
3
AMR Coral Gables/Miami, Formerly Clinical Research of South Florida, an AMR company (Clinic) Site Number : 8400004
Coral Gables, Florida, United States, 33134
4
Research Centers of America Site Number : 8400003
Hollywood, Florida, United States, 33024